Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, noviembre 17
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Scienture Holdings Inc
SCNX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$2.99
0.09
3.1%
al cierre: Nov 13, 4:00 PM EST
$2.91
0.01
0.34%
Premercado: 4:00 AM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Dividendos
Comparar
Informe de acciones
Scienture Holdings Financials
Scienture Holdings (SCNX) financial statements — income, revenue, gross margin and key metrics.
Ganancias:
Los beneficios de Q3 2026 se publicaron el lun nov 16th, antes de la apertura del mercado
Earnings & Guidance News
PRO
Scienture Holdings Q3 EPS $(3.76) Misses $(1.57) Estimate, Sales $1.255M Beat $1.220M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(3.76) per share which missed the analyst consensus estimate of $(1.57) by 139.49 percent. This is a 21.01 percent increase over losses of $(4.76) per share
Benzinga Newsdesk
PRO
Scienture Holdings Reports Preliminary Q3 Revenue Growth To $1.22M; Co Targeting Profitability In 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™Two FDA-Approved Commercial Products
Benzinga Newsdesk
PRO
SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers
Benzinga Newsdesk
PRO
EXCLUSIVE: Scienture Reports Preliminary Q3 Sales of ~$1.22M, Sequential Growth of 256%, Arbli Wholesale Unit Sales Increased 74% Sequentially
Benzinga Newsdesk
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.
Vandana Singh
PRO
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 85.42 percent increase over losses of $(0.48) per share
Benzinga Newsdesk